erythropoietin

Sequence and processing identity

Record the reference and evidence needed to distinguish erythropoietin protein from its gene, transcript and precursor representation.

1. Which species, protein accession and sequence version define the erythropoietin being represented? definition
2. Does the evidence concern mature protein, precursor protein, EPO transcript or only a name assigned to a sample? boundary

Glycoform and analogue status

Record sequence changes, glycosylation evidence and chemical modifications before deciding whether material instantiates this entry or needs a neighbouring-model relation.

1. Which sequence, glycosylation or conjugation differences from the chosen erythropoietin reference have actually been measured? measurement
2. Does the registry place this named epoetin or modified analogue inside erythropoietin, or require a relation to a separately registered thing? boundary

Endogenous or recombinant evidence

Represent origin as an evidence-qualified attribution, allowing mixed and unknown cases.

1. What production record or validated analytical evidence supports an endogenous, recombinant or mixed origin? provenance
2. If a tissue of synthesis is asserted, what evidence distinguishes synthesis there from erythropoietin merely being present there? provenance

Matrix and time context

Tie observations to a matrix, collection time and relevant exposure history without assigning specimen properties to the molecule itself.

1. In which serum, plasma, urine, tissue extract or manufactured preparation was erythropoietin observed, and when was it obtained? provenance
2. Is recent exposure to an erythropoiesis-stimulating agent documented, absent from the record or explicitly unknown? provenance

Analyte specificity and interference

Record validated recognition of relevant forms and evidence for interference rather than assuming every EPO assay measures them equally.

1. Which endogenous erythropoietin forms, recombinant epoetins or modified analogues does this assay demonstrably detect? measurement
2. What matrix effects, antibody interference or out-of-range behaviour were assessed for this result? measurement

Comparable erythropoietin results

Qualify comparisons using method and calibration evidence, retaining below-limit results as censored observations rather than zero.

1. What value, unit, calibrator, quantification limits and applicable laboratory reference interval accompany the result? measurement
2. Do the assays and calibrators support comparison with the earlier result, or is a method-specific qualification required? action

Binding versus potency

Record receptor-binding evidence and functional potency separately, including controls needed to attribute a response to erythropoietin.

1. Was EPOR binding, receptor-dependent signalling or an erythroid-cell response measured, and in which species and assay system? measurement
2. Which reference standard and specificity controls support attributing the measured potency to erythropoietin? measurement

Abundance-response discordance

Record whether concentration and observed erythropoietic response agree, leaving diagnosis and treatment decisions to linked clinical models.

1. Which time-linked haemoglobin, reticulocyte, iron-status, renal-function and oxygenation observations are available to contextualise this erythropoietin result? measurement
2. If abundance and response appear discordant, what evidence is missing before assigning the discrepancy to erythropoietin inactivity or inadequate production? boundary

Erythropoietin stability evidence

Assess handling against specimen- or preparation-specific evidence rather than assigning one storage rule to all erythropoietin.

1. What temperature, elapsed-time, agitation and freeze-thaw history is documented for this erythropoietin-containing material? provenance
2. Do applicable stability data or integrity assays support its continued use for the proposed erythropoietin measurement or activity assay? action

Supported next use

Record whether evidence supports analysis, research use, reassessment or referral to the governing medicinal-product record.

1. Is the material intended for endogenous-EPO testing, a reference standard, a functional experiment or use as a medicinal product? definition
2. Which missing identity, potency, integrity or product-link evidence must be resolved before that specific use is supported? action

Kinds and varieties

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Endogenous human EPO (the circulating mixture of serum and urinary glycoforms)
• Epoetin alfa (CHO-derived recombinant originator used as the clinical reference ESA)
• Other recombinant epoetin INN glycoforms (beta, theta, zeta, kappa, omega, delta), distinguished by host cell and glycosylation
• Darbepoetin alfa (engineered analogue with two extra N-glycans)
• Methoxy polyethylene glycol-epoetin beta (continuous erythropoietin receptor activator, CERA)
• Licensed epoetin biosimilars of an originator epoetin
• EPO-mimetic peptides (for example peginesatide; withdrawn from clinical use)
• Non-clinical research and veterinary EPO preparations

1. Which of these kinds and varieties hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Identifiers and schemes

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Wikidata - Q218706 - Item for the hormone erythropoietin, not a branded medicinal product.
• UniProtKB - P01588 - Canonical human EPO protein entry.
• HGNC - EPO (HGNC:3415) - Human gene symbol for the EPO locus.
• NCBI Gene - 2056 - Human EPO gene identifier.
• CAS Registry Number - 11096-26-7 - Erythropoietin as a substance; epoetin alfa is separately 113427-24-0.
• ATC - B03XA01 - WHO ATC for erythropoietin; darbepoetin alfa is B03XA02 and methoxy PEG-epoetin beta is B03XA03.
• WHO INN - epoetin alfa | epoetin beta | epoetin theta | epoetin zeta | darbepoetin alfa - INN stem epoetin names the recombinant hormone class; darbepoetin is the glycoengineered analogue.

1. Which of these identifiers and schemes hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Standards and regulation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• WHO International Nonproprietary Names for epoetins and related ESAs (World Health Organization)
• WHO International Standard for recombinant erythropoietin used to assign IU potency (WHO Expert Committee on Biological Standardization)
• European Pharmacopoeia monograph Erythropoietin concentrated solution (EDQM)
• EMA guideline on similar biological medicinal products containing recombinant erythropoietins, EMEA/CHMP/BMWP/301636/2008 Rev. 1 (European Medicines Agency)
• US FDA biologics licensing and boxed-warning labeling for erythropoiesis-stimulating agents (U.S. Food and Drug Administration)
• ICH Q6B specifications for biotechnological products, applied to EPO identity, glycosylation and potency (ICH)
• WADA Prohibited List S2, erythropoietin-receptor agonists (World Anti-Doping Agency)
• KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (KDIGO)

1. Which of these standards and regulation hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Real-world use

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Replacement ESA therapy for anemia of chronic kidney disease, given intravenously on dialysis or subcutaneously in clinic or at home
• Selected treatment of chemotherapy-associated anemia, constrained by tumor-progression and thrombosis warnings
• Perioperative use to support autologous donation or to reduce allogeneic transfusion in some orthopedic and cardiac pathways
• Diagnostic serum EPO measurement to help separate polycythemia vera (typically suppressed EPO) from hypoxia- or EPO-driven secondary erythrocytosis
• Anti-doping testing of blood and urine from endurance athletes for recombinant isoforms
• Protocol use in some neonatal units for anemia of prematurity

1. Which of these real-world use hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Typical measurements

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Adult serum immunoreactive EPO (common clinical immunoassay reference interval) - 2.6-18.5 (method-dependent) - IU/L
• Mature human polypeptide mass - 18.4 - kDa
• Apparent mass of the circulating glycoprotein - 30-34 - kDa
• Amino-acid residues in the mature human protein - 165 - aa
• N-linked glycosylation sites on native human EPO - 3 - sites
• Epoetin alfa terminal plasma half-life after an intravenous dose - 4-13 - h
• Hemoglobin range targeted during ESA therapy in contemporary CKD practice (not a physiological EPO range) - 100-115 - g/L

1. Which of these typical measurements hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Failure modes and hazards

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Anti-EPO antibody-mediated pure red cell aplasia, historically clustered with some epoetin alfa formulations given subcutaneously
• Venous and arterial thrombosis, stroke, and excess mortality when ESAs are used to push hemoglobin toward the normal range
• New or worsening hypertension, and seizures when hematocrit rises rapidly
• Signals of shortened survival or tumor progression in some oncology indications
• ESA hyporesponsiveness from iron deficiency, inflammation, secondary hyperparathyroidism, or concurrent ACE-inhibitor use
• Immunogenicity after a change of formulation, container, or route
• Illicit endurance-sport use, including micro-dosing intended to evade isoform tests

1. Which of these failure modes and hazards hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Regional variation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• The United States long used originator epoetin alfa (Epogen/Procrit) and darbepoetin; the EU licensed multiple epoetin biosimilars earlier and more widely
• Japan has locally prominent products such as epoetin kappa and epoetin beta pegol that are uncommon as first-line ESAs elsewhere
• Vernacular "EPO" and "erythropoietin" versus the INN "epoetin"; darbepoetin and CERA keep separate brand families by market
• Dialysis ESA dosing is shaped by US Medicare bundled payment in a way that does not apply in fee-for-service systems
• Anti-doping isoform maps are calibrated to the recombinant products actually circulating in a region, so the laboratory signature of "rEPO" is not globally identical

1. Which of these regional variation hold for the sense of erythropoietin this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Darbepoetin alfa - Five N-glycans and a longer half-life versus native/epoetin three-N-glycan EPO; IEF or SAR-PAGE shows a more acidic, slower-migrating isoform ladder.
• HIF-prolyl hydroxylase inhibitors (for example roxadustat, vadadustat) - They raise endogenous EPO rather than supplying recombinant protein; circulating EPO retains the native isoform pattern instead of an rEPO ladder.
• G-CSF (filgrastim and related CSFs) - Myeloid growth factor acting on G-CSF receptor, not EPO receptor; increases neutrophils, not red-cell mass.
• Thrombopoietin-receptor agonists - Platelet-lineage agonists (TPO receptor); they do not bind EPO receptor or raise hemoglobin as their primary effect.
• Packed red-cell transfusion - Raises hemoglobin without EPO-receptor agonism; measured EPO typically falls after an adequate transfusion.
• Polycythemia vera - Clonal erythrocytosis with suppressed serum EPO and, in most cases, a JAK2 mutation; secondary erythrocytosis shows elevated or inappropriately normal EPO and no JAK2 driver.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of erythropoietin this model covers, and on what evidence? provenance